transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2024-11-4-342-350transmed-846Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHБелок S100b как биологический маркер повреждения нервной ткани у лабораторных животных в доклинических исследованияхS100b protein as a biological marker of nerve tissue damage in laboratory animals in preclinical studieshttps://orcid.org/0000-0002-2689-6891ВавиловаВ. А.VavilovaV. A.

Вавилова Валерия Александровна, руководитель группы токсикологии, отдел специфической токсикологии и микробиологии

Заводская ул., д. 3, корп. 245, г. п. Кузьмоловский, Ленинградская область, 188663

Valeriya A. Vavilova, Head of the Toxicology Group, Department of Specific Toxicology and Microbiology

Zavodskaya str., 3, building 245, Kuzmolovsky settlement, Leningrad region, 188663

vavilova.va@doclinika.ruФаустоваН. М.FaustovaN. M.

Фаустова Наталья Михайловна, к.х.н., руководитель лаборатории иммуноферментного анализа

Заводская ул., д. 3, корп. 245, г. п. Кузьмоловский, Ленинградская область, 188663

Natalia M. Faustova, PhD, Head of the Laboratory of enzyme Immunoassay

Zavodskaya str., 3, building 245, Kuzmolovsky settlement, Leningrad region, 188663

ПелешокА. А.PeleshokA. A.

Пелешок Андрей Андреевич, стажер-исследователь, отдел молекулярной фармакологии

Заводская ул., д. 3, корп. 245, г. п. Кузьмоловский, Ленинградская область, 188663

Andrei A. Peleshok, research intern, Department of Molecular Pharmacology

Zavodskaya str., 3, building 245, Kuzmolovsky settlement, Leningrad region, 188663

КрышеньК. Л.Kryshen’K. L.

Крышень Кирилл Леонидович, к.б.н., руководитель отдела специфической токсикологии и микробиологии

Заводская ул., д. 3, корп. 245, г. п. Кузьмоловский, Ленинградская область, 188663

Kirill L. Kryshen’, PhD, Head of the Department of Specific Toxicology and Microbiology

Zavodskaya str., 3, building 245, Kuzmolovsky settlement, Leningrad region, 188663

МакароваМ. Н.MakarovaM. N.

Макарова Марина Николаевна, д.м.н., директор

Заводская ул., д. 3, корп. 245, г. п. Кузьмоловский, Ленинградская область, 188663

Marina N. Makarova, MD, Director

Zavodskaya str., 3, building 245, Kuzmolovsky settlement, Leningrad region, 188663

МакаровВ. Г.MakarovV. G.

Макаров Валерий Геннадьевич, д.м.н., научный руководитель

Заводская ул., д. 3, корп. 245, г. п. Кузьмоловский, Ленинградская область, 188663

Valery G. Makarov, MD, Scientific director

Zavodskaya str., 3, building 245, Kuzmolovsky settlement, Leningrad region, 188663

АО «НПО «Дом Фармации»РоссияResearch and manufacturing company “Home оf Pharmacy”Russian Federation202401092024114342350Copyright © Вавилова В.А., Фаустова Н.М., Пелешок А.А., Крышень К.Л., Макарова М.Н., Макаров В.Г., 20242024Вавилова В.А., Фаустова Н.М., Пелешок А.А., Крышень К.Л., Макарова М.Н., Макаров В.Г.Vavilova V.A., Faustova N.M., Peleshok A.A., Kryshen’ K.L., Makarova M.N., Makarov V.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/846

Актуальность. Для доклинических исследований лекарственных средств актуальной задачей является выбор специфических биохимических маркеров, отражающих повреждения центральной нервной системы в токсикологических и фармакологических экспериментах. Одним из таких маркеров может являться белок S100b, уровень которого позволит оценивать повреждение центральной нервной системы различного генеза. Цель. Целью исследования являлась оценка изменения уровня белка S100b в крови крыс и мышей, в гомогенатах головного мозга мышей при повреждениях тканей мозга различного генеза. Материалы и методы. Исследование проводилось на самцах аутбредных крыс и мышей. Суммарно было использовано 62 животных: 47 крыс и 15 мышей. Для определения концентрации белка S100b методом иммуноферментного анализа использовали наборы Lifespan Biosciences (США): Rat S100b/S100 beta Elisa kit (Sandwich Elisa) — для крыс и Mouse S100b/S100 beta Elisa kit (Sandwich Elisa) — для мышей. Статистический анализ выполняли с помощью лицензированного программного обеспечения GraphPad Prism 9. Результаты. Изменения концентрации белка S100b изучали на моделях алкогольной нейропатии, билатеральной и фокальной церебральной ишемии, черепно-мозговой травмы. Формирование всех патологий приводило к повышению концентрации белка S100b как в плазме крови, так и в тканях головного мозга (при черепно-мозговой травме). Для алкогольной нейропатии, фокальной церебральной ишемии и черепно-мозговой травмы изменения уровня этого маркера достигали статистической значимости. Заключение. Повышение концентрации S100b является признаком повреждения нейронов в результате воздействия ишемических, травматических и токсических факторов, а также при гипогликемических состояниях. Таким образом, белок S100b может применяться в доклинических исследованиях в качестве маркера повреждения головного мозга, реагирующего на повреждения различного генеза в исследованиях фармакодинамики и фармакологической безопасности лекарственных препаратов.

Background. For preclinical studies of drugs a relevant task is the selection of specific biochemical markers reflecting damage to the central nervous system, both in toxicological and pharmacological experiments. One of such markers may be protein S100b, the level of which will make it possible to assess the damage of the central nervous system of various genesis. Objective. The aim of the study was to assess changes in the level of S100b protein in the blood and in brain homogenates in brain tissue injuries of various genesis. Design and methods. The study was conducted on males of outbred rats and mice. A total of 62 animals were used: 47 rats and 15 mice. To determine the concentration of S100b protein, ELISA kits Rat S100b/S100 beta Elisa kit (Sandwich Elisa) were used) for rats and Mouse S100b/S100 beta Elisa kit (Sandwich Elisa) for mice. Statistical analysis was performed using licensed GraphPad Prism 9 software. Results: Changes of protein S100B was explored on models of alcohol neuropathy, bilateral and focal cerebral ischemia, traumatic brain injury. Forming of all pa[1]thologies led to increasing of protein S100B both in blood plasma and in brain tissues in case of traumatic brain injury. For alcohol neuropathy, focal and cerebral ischemia and traumatic brain injury changings of this marker level reached statistic meaning. Conclusion. Increased concentration of S100b is a sign of neuronal damage as a result of ischemic, traumatic and toxic factors, as well as in hypoclycemic conditions. Thus, protein S100b can be used in preclinical studies as a marker of brain damage, responding to damage of various genesis in studies of pharmacodynamics and pharmacological safety of drugs.

алкогольная нейропатиябилатеральная ишемиякрысымышичерепно-мозговая травмаS100balcoholic neuropathybilateral ischemiacranio-cerebral traumamiceprotein S100bratsReferencesArrais AC, et al. S100B protein: general characteristics and pathophysiological implications in the Central Nervous System //International Journal of Neuroscience. 2022;132:313–321. DOI: 10.1080/00207454.2020.1807979Arrais AC, et al. S100B protein: general characteristics and pathophysiological implications in the Central Nervous System //International Journal of Neuroscience. 2022;132:313–321. DOI: 10.1080/00207454.2020.1807979Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease //Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2020; 1867( 6):118677. DOI: 10.1016/j.bbamcr.2020.118677Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease //Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2020; 1867( 6):118677. DOI: 10.1016/j.bbamcr.2020.118677Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature) //Biochemical and biophysical research communications. 2004; 322(4):1111–1122. DOI: 10.1016/j.bbrc.2004.07.096Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature) //Biochemical and biophysical research communications. 2004; 322(4):1111–1122. DOI: 10.1016/j.bbrc.2004.07.096Шайтанова Т.Ю., Саскин В.А., Недашковский Э.В. Практическое применение белка S-100B при острой цереброваскулярной патологии. Вестник анестезиологии и реаниматологии. 2014; 2:63–71.Shaitanova TYu, Siskin VA, Nedashkovsky EV. Practical application of S-100b protein in acute cerebrovascular disease. Messenger of anesthesiology and resuscitation. 2014;2:63–71. In RussianLue LF, Yan SD, Stern DM, et al. Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Curr Drug Targets CNS Neurol Disord. 2005;4(3):249–266. DOI: 10.2174/1568007054038210.Lue LF, Yan SD, Stern DM, et al. Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Curr Drug Targets CNS Neurol Disord. 2005;4(3):249–266. DOI: 10.2174/1568007054038210.Белобородова Н.В., Дмитриева И.Б., Черневская Е.А. Диагностическая значимость белка s100b при критических состояниях. Общая реаниматология. 2011;7(6):72–76. DOI: 10.15360/1813-9779-2011-6-72.Beloborodova NV, Dmitriyeva IB, Chernevskaya EA. Diagnostic Value of S100B Protein in Critical Conditions. General Reanimatology. 2011;7(6):72–76. In RussianDonato R, Sorci G, Riuzzi F, et al. S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008–1022. DOI: 10.1016/j.bbamcr.2008.11.009.Donato R, Sorci G, Riuzzi F, et al. S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008–1022. DOI: 10.1016/j.bbamcr.2008.11.009.Heizmann CW. The multifunctional S100 protein family. Methods Mol Biol. 2002;172:69–80. DOI: 10.1385/1-59259-183-3:069.Heizmann CW. The multifunctional S100 protein family. Methods Mol Biol. 2002;172:69–80. DOI: 10.1385/1-59259-183-3:069.Траилин А.В., Левада О.А. Белок S100В: нейробиология, значение при неврологической и психиатрической патологии. Международный неврологический журнал. 2009; (1):166–175].Trailin AV, Levada OA. S100В-protein: Neurobiology, significance in neurological and psychiatric pathology. International Journal of Neurology. 2009; 1:166–175. In RussianWang KK, Yang Z, Zhu T, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018; 18(2):165–180. DOI: 10.1080/14737159.2018.1428089.Wang KK, Yang Z, Zhu T, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018; 18(2):165–180. DOI: 10.1080/14737159.2018.1428089.Sandhir R, Onyszchuk G, Berman NE. Exacerbated glial response in the aged mouse hippocampus following controlled cortical impact injury. Exp Neurol. 2008; 213(2):372–380. DOI: 10.1016/j.expneurol.2008.06.013.Sandhir R, Onyszchuk G, Berman NE. Exacerbated glial response in the aged mouse hippocampus following controlled cortical impact injury. Exp Neurol. 2008; 213(2):372–380. DOI: 10.1016/j.expneurol.2008.06.013.Kellermann I, Kleindienst A, Hore N, et al. Early CSF and Serum S100B Concentrations for Outcome Prediction in Traumatic Brain Injury and Subarachnoid Hemorrhage. Clin Neurol Neurosurg. 2016;145:79–83. DOI: 10.1016/j.clineuro.2016.04.005.Kellermann I, Kleindienst A, Hore N, et al. Early CSF and Serum S100B Concentrations for Outcome Prediction in Traumatic Brain Injury and Subarachnoid Hemorrhage. Clin Neurol Neurosurg. 2016;145:79–83. DOI: 10.1016/j.clineuro.2016.04.005.Di Battista AP, Buonora JE, Rhind SG, et al. Blood Biomarkers in Moderate-To-Severe Traumatic Brain Injury: Potential Utility of a Multi-Marker Approach in Characterizing Outcome. Front Neurol. 2015;6:110. DOI:10.3389/fneur.2015.00110.Di Battista AP, Buonora JE, Rhind SG, et al. Blood Biomarkers in Moderate-To-Severe Traumatic Brain Injury: Potential Utility of a Multi-Marker Approach in Characterizing Outcome. Front Neurol. 2015;6:110. DOI:10.3389/fneur.2015.00110.Celikbilek A, Akyol L, Sabah S, et al. S100B as a glial cell marker in diabetic peripheral neuropathy. Neuroscience letters. 2014;558:53–57. DOI: 10.1016/j.neulet.2013.10.067.Celikbilek A, Akyol L, Sabah S, et al. S100B as a glial cell marker in diabetic peripheral neuropathy. Neuroscience letters. 2014;558:53–57. DOI: 10.1016/j.neulet.2013.10.067.Кашкин В.А. Анальгетический эффект кардиотонических стероидов на фоне алкогольной нейропатии у крыс. Интегративная физиология. 2020;1(2):133–139]. DOI: 10.33910/2687-1270-2020-1-2-133-139.Kashkin VA. Analgesic effect of cardiotonic steroids against the background of alcoholic neuropathy in the rat. Integrative Physiology. 2020; 1(2):133–139. In RussianChen Y, Constantini S, Trembovler V, et al. An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. J Neurotrauma. 1996; 13(10):557–568. DOI: 10.1089/neu.1996.13.557.Chen Y, Constantini S, Trembovler V, et al. An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. J Neurotrauma. 1996; 13(10):557–568. DOI: 10.1089/neu.1996.13.557.Flierl MA, Stahel PF, Beauchamp KM, et al. Mouse closed head injury model induced by a weight-drop device. Nat Protoc. 2009;4(9):1328–1337. DOI:10.1038/nprot.2009.148.Flierl MA, Stahel PF, Beauchamp KM, et al. Mouse closed head injury model induced by a weight-drop device. Nat Protoc. 2009;4(9):1328–1337. DOI:10.1038/nprot.2009.148.Tsenter J, Beni-Adani L, Assaf Y, et al. Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions. J Neurotrauma. 2008;25(4):324–333. DOI:10.1089/neu.2007.0452.Tsenter J, Beni-Adani L, Assaf Y, et al. Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions. J Neurotrauma. 2008;25(4):324–333. DOI:10.1089/neu.2007.0452.Aski ML, Rezvani ME, Khaksari M, et al. Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. Iran J Basic Med Sci. 2018; 21(1):53–58. DOI: 10.22038/IJBMS.2017.23195.5865.Aski ML, Rezvani ME, Khaksari M, et al. Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. Iran J Basic Med Sci. 2018; 21(1):53–58. DOI: 10.22038/IJBMS.2017.23195.5865.Cechetti F, Worm PV, Pereira LO, et al. The modified 2VO ischemia protocol causes cognitive impairment similar to that induced by the standard method, but with a better survival rate. Braz J Med Biol Res. 2010;43(12):1178–1183. DOI: 10.1590/s0100-879x2010007500124.Cechetti F, Worm PV, Pereira LO, et al. The modified 2VO ischemia protocol causes cognitive impairment similar to that induced by the standard method, but with a better survival rate. Braz J Med Biol Res. 2010;43(12):1178–1183. DOI: 10.1590/s0100-879x2010007500124.Koizumi J, Yoshida Y, Nakazawa T, et al. Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke. 1986; 85:1–8. DOI: 10.3995/jstroke.8.1.Koizumi J, Yoshida Y, Nakazawa T, et al. Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke. 1986; 85:1–8. DOI: 10.3995/jstroke.8.1.Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91. DOI: 10.1161/01.str.20.1.84.Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91. DOI: 10.1161/01.str.20.1.84.Dimopoulos C, Damaskos C, Papadakis M, et al. Expression of S100B protein in ischemia/reperfusion-induced brain injury after cyclosporine therapy: a biochemical serum marker with prognostic value? Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2019;(25): 1637. DOI: 10.12659/MSM.912810.Dimopoulos C, Damaskos C, Papadakis M, et al. Expression of S100B protein in ischemia/reperfusion-induced brain injury after cyclosporine therapy: a biochemical serum marker with prognostic value? Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2019;(25): 1637. DOI: 10.12659/MSM.912810.Мазукина Е.В., Шекунова Е.В., Кашкин В.А. и др. Влияние умеренной гипогликемии на уровень белка S100b в крови и гиппокампе крыс. Лабораторные животные для научных исследований. 2019;(1):95–107. DOI: 10.29296/2618723X-2019-01-07.Mazukina EV, Shekunova EV, Kashkin VA, et al. Recurrent hypoglycemia affects S100b plasma concentration and S100b hippocampal expression in rats. Laboratory animals for science. 2019;(1):95–107. In RussianMichetti F, D’Ambrosi N, Toesca A, et al. The S100B story: from biomarker to active factor in neural injury. J Neurochem. 2019;148(2):168–187. DOI: 10.1111/jnc.14574.Michetti F, D’Ambrosi N, Toesca A, et al. The S100B story: from biomarker to active factor in neural injury. J Neurochem. 2019;148(2):168–187. DOI: 10.1111/jnc.14574.Michetti F, Clementi ME, Di Liddo R, et al. The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker. Int J Mol Sci. 2023; 24(11):9605. DOI: 10.3390/ijms24119605.Michetti F, Clementi ME, Di Liddo R, et al. The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker. Int J Mol Sci. 2023; 24(11):9605. DOI: 10.3390/ijms24119605.Pham N, Fazio V, Cucullo L, et al. Extracranial sources of S100B do not affect serum levels [published correction appears in PLoS One. 2010;5(10). DOI: 10.1371/annotation/bdcb41f2-a320-4401-a6ab-86e71738597e]. PLoS One. 2010;5(9):e12691. DOI: 10.1371/journal.pone.0012691Pham N, Fazio V, Cucullo L, et al. Extracranial sources of S100B do not affect serum levels [published correction appears in PLoS One. 2010;5(10). DOI: 10.1371/annotation/bdcb41f2-a320-4401-a6ab-86e71738597e]. PLoS One. 2010;5(9):e12691. DOI: 10.1371/journal.pone.0012691Morera-Fumero AL, Abreu-Gonzalez P, HenryBenitez M, et al. Summer/winter changes in serum S100B protein concentration as a source of research variance. J Psychiatr Res. 2013;47(6):791–795. DOI: 10.1016/j.jpsychires.2013.03.001.Morera-Fumero AL, Abreu-Gonzalez P, HenryBenitez M, et al. Summer/winter changes in serum S100B protein concentration as a source of research variance. J Psychiatr Res. 2013;47(6):791–795. DOI: 10.1016/j.jpsychires.2013.03.001.Kural A, Tekin Neijmann S, Toker A, et al. Evaluation of rat major celluler prion protein for early diagnosis in experimental rat brain trauma model. Turkish Journal of Trauma and Emergency Surgery. 2020;26(1):1–8. DOI: 10.5505/tjtes.2018.46923.Kural A, Tekin Neijmann S, Toker A, et al. Evaluation of rat major celluler prion protein for early diagnosis in experimental rat brain trauma model. Turkish Journal of Trauma and Emergency Surgery. 2020;26(1):1–8. DOI: 10.5505/tjtes.2018.46923.Netto CB, Conte S, Leite MC, et al. Serum S100B protein is increased in fasting rats. Arch Med Res. 2006;37(5):683–686. DOI: 10.1016/j.arcmed.2005.11.005.Netto CB, Conte S, Leite MC, et al. Serum S100B protein is increased in fasting rats. Arch Med Res. 2006;37(5):683–686. DOI: 10.1016/j.arcmed.2005.11.005.

The authors declare that there are no conflicts of interest present.